Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...

The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...

BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.